 |
pembrolizumab |
|---|---|
| Trade Name | Keytruda |
| Orphan Indication | Nasopharyngeal carcinoma |
| USA Market Approval | USA |
| USA Designation Date | 2016-10-11 00:00:00 |
| Sponsor | Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co.;1 Merck Drive;Whitehouse Station, New Jersey, 08889 |
